IBCG AUA 2024 Bladder Cancer Forum

Exploring the Complexities of Bladder Cancer Surveillance: Cytology, UroVysion, and Beyond - Komal Pohar & Kelly Bree

The Evolving Role of Radical Cystectomy in the Era of Bladder-Sparing Therapies - Sima Porten & Roger Li

Managing Variant Histology in High-Risk Non-Muscle Invasive Bladder Cancer - Michael Cookson & Paolo Gontero

To TURBT or Not to TURBT? Evaluating Treatment Options for Recurrent Low-Grade, Intermediate-Risk Bladder Tumors - Sarah Psutka & Param Mariappan

Treatment Options for Advanced Urothelial Cancer Post-EV-302 - Shilpa Gupta & Karima Oualla

Timing and Rationale for Repeat TURBT: Perspectives on Improving Bladder Cancer Outcomes - Badrinath Konety & Jeremy Teoh

Defining Standard and Extended Pelvic Lymphadenectomy in Bladder Cancer Surgery - Seth Lerner & Siamak Daneshmand

Optimizing BCG Therapy in Bladder Cancer: Expert Insights on Managing Toxicity and Maximizing Efficacy - Badrinath Konety & Wassim Kassouf

Timing of Radical Cystectomy in BCG Unresponsive Disease - Patrick Hensley

The Controversy Over Radical Cystectomy for N1 and N2 Bladder Cancer: Experts Weigh In - Brant Inman & Yair Lotan

The Impact of Variant Histology on the Management of Patients with Bladder Cancer - Mario Fernandez and Michael A. O’Donnell

The Role of Risk-Stratified Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer Who Are Undergoing Radical Cystectomy - Arlene O. Siefker-Radtke and Shilpa Gupta

Do We Need to Perform Radical Cystectomy for Patients Who are cT0 After Neoadjuvant Chemotherapy? - Gary Steinberg & John Taylor